The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not ...

Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, Reuters writes ...

A doctor has revealed the truth behind what is being dubbed the 'Ozempic vulva' as the drug surges in popularity.

Novo Nordisk A/S said it has implemented a global hiring freeze as the Danish maker of weight-loss drugs seeks to cut costs ...

The weight loss drug, which was previously also used to treat diabetes, may be having an unexpected impact on a rather sensitive body part ...

Wegovy-maker Novo Nordisk has implemented a global hiring freeze, which covers job roles that are not critical for its ...

The side effect is rare, according to a new study, but is also the subject of multiple lawsuits, including two filed by Long ...

The manufacturer of Ozempic (and other Semaglutide brands) faces over $2 billion in lawsuits filed by over 1,800 patients claiming blindness, stomach paralysis, and more.

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...